A new production line that is the result of the company’s internal development and innovation is one of the last goals achieved over this 125-year business period, besides the production of the Pecsys© system for the innovative nasal spray in the treatment of serious pain, recently introduced in the European Association for Palliative Care (EAPC) and the European Society for Medical Oncology (ESMO) guidelines.
Thanks to the new production line inaugurated at the Scandicci facility near Florence, an innovative drug is under production. It is a nasal spray to control severe pain due to serious oncological pathologies which cannot be relieved with standard therapies. The economic investment exceeds 5 million Euro. The drug is manufactured exclusively for Italy and Europe.
The nasal spray, a formulation characterized by strong technological innovation, well matches Molteni’s mission to fight against pain started in the early 20th century. In particular, as far as the complex product packaging is concerned, the formulation, based on an opiate, is sprayed and optimally vaporized thanks to a pectin excipient (Pecsys© patent), which ensures constancy of the dose delivered and actually administered to the patient. The assurance and solidity of the production process has been a strong point of Molteni Farmaceutici’s expertise ever since the production of its first sterile vials for hypodermic use more than a century ago. For this reason, after having been involved as a logistics platform for the import (so far the drug has only been produced in the USA), quality control and marketing in Europe since 2009, Molteni was offered by the Anglo-American owners of the drug the opportunity to set up a facility for its actual production in Europe.